Theravance Biopharma (NASDAQ:TBPH) SVP Rhonda Farnum Sells 31,067 Shares

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the sale, the senior vice president directly owned 232,699 shares in the company, valued at approximately $3,248,478.04. The trade was a 11.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Theravance Biopharma Stock Down 0.6%

Shares of TBPH stock traded down $0.09 during trading on Wednesday, hitting $13.83. The company had a trading volume of 538,359 shares, compared to its average volume of 607,018. The stock’s 50-day moving average is $18.30 and its two-hundred day moving average is $16.88. The stock has a market capitalization of $700.77 million, a price-to-earnings ratio of 24.26 and a beta of 0.17. Theravance Biopharma, Inc. has a 52 week low of $7.90 and a 52 week high of $21.03.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on TBPH shares. HC Wainwright lifted their price target on Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. B. Riley Financial restated a “neutral” rating and issued a $14.00 target price (down from $28.00) on shares of Theravance Biopharma in a research report on Wednesday, March 4th. BTIG Research reduced their price target on shares of Theravance Biopharma from $40.00 to $21.00 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a research note on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.60.

Institutional Trading of Theravance Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Quarry LP purchased a new position in shares of Theravance Biopharma in the third quarter worth $26,000. Caitong International Asset Management Co. Ltd grew its holdings in Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,411 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 515 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 781 shares during the period. Finally, CIBC Private Wealth Group LLC raised its stake in shares of Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after acquiring an additional 4,662 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.